Nevirapine 200 mg Tablets

Nevirapine 200 mg tablet options

Nevirapine 200 mg is an oral tablet used as one component of combination antiretroviral therapy for HIV. The product choice in our catalogue is not between different strengths or dosage forms: we offer the same 200 mg tablet in package quantities ranging from 20 to 360 tablets. The relevant decision is therefore how many tablets correspond to the regimen and supply period established by your prescriber.

Package value matters, but it should be considered alongside the prescribed dosing schedule, the possibility that treatment may change, the labelled expiry date, and appropriate storage. Nevirapine has important initiation, interruption, and monitoring requirements, so a package should not be selected solely because it has a lower cost per tablet.

Package sizes and unit value

The comparison below presents our available package quantities, current prices, per-tablet values, and any relative savings shown for the listed options. It provides the figures you need to compare package value without relying on competitor prices, market averages, or assumptions about insurance coverage.

A lower unit cost does not automatically make a larger package the right option. Consider whether the quantity is consistent with the prescription, whether the treatment plan is stable, and whether the tablets can be used before their expiry date. The package comparison is a purchasing aid, not a substitute for dosing or treatment advice.

How should strength and quantity be matched to treatment?

Our Nevirapine listing is for one strength and form: a 200 mg tablet taken by mouth. Package size does not identify a starter pack, maintenance pack, trial supply, or pediatric format. Any quantity selected must be interpreted in the context of the directions provided by the prescriber and the specific product label.

Nevirapine commonly requires a 14-day lead-in period when treatment is initiated. The dosing frequency during that period differs from the subsequent maintenance schedule to reduce the risk of rash. This means a package count cannot be converted into a treatment duration without knowing the prescribed regimen. Pediatric dosing may also depend on age and body size, and a 200 mg tablet is not suitable for every child.

• Confirm that the prescription specifies the 200 mg tablet rather than another formulation or strength.
• Calculate the required quantity from the prescribed schedule, including any lead-in instructions, rather than assuming one tablet per day.
• Allow appropriate ordering time so that an established antiretroviral regimen is not interrupted.
• Do not order substantially beyond the expected supply period simply to obtain a lower unit price.

If nevirapine has been stopped for several days, clinical advice may be needed before it is restarted because the lead-in schedule may need to be repeated. Do not use a new package to restart treatment without instructions from the prescriber managing the regimen.

Brand and generic context

Viramune is a brand name associated with nevirapine, while our product is listed under the generic name Nevirapine. Both names refer to the active ingredient nevirapine, and Viramune has been marketed in a 200 mg oral tablet form. However, a generic-name listing should not be assumed to be identical to a particular branded product in tablet appearance, inactive ingredients, packaging, manufacturer, or product identification.

Check the label and available product details for the specific tablets supplied. A pharmacist or prescriber can advise whether a particular authorized generic product is appropriate when changing from a branded product or another manufacturer. Viramune is provided here as brand-name context and is not represented as an option in our catalogue.

What is nevirapine used for?

Nevirapine is a non-nucleoside reverse transcriptase inhibitor, commonly abbreviated as an NNRTI. It is used with other antiretroviral medicines to treat HIV infection. It should not be used as the only active medicine in an HIV regimen because combination therapy is required to suppress viral replication and reduce the risk of drug resistance.

A treatment team may consider nevirapine in relation to other NNRTIs, such as efavirenz, rilpivirine, etravirine, or doravirine, as well as antiretrovirals from other drug classes. Those medicines are not direct package substitutes: changing one component can affect interactions, resistance coverage, monitoring, and the suitability of the full regimen.

Readers reviewing the broader treatment context can browse our HIV category or the wider Anti Viral & Immunity category. These links provide catalogue navigation and do not imply that products should be combined without clinical direction.

Mechanism and practical use

Nevirapine binds to HIV reverse transcriptase and inhibits the enzyme. This interferes with the process HIV uses to copy its genetic material. Its mechanism differs from that of nucleoside or nucleotide reverse transcriptase inhibitors, which is one reason medicines from different classes may be combined in a complete antiretroviral regimen.

The tablets are taken by mouth according to a schedule set by the prescriber. The 14-day lead-in regimen is an important part of initiation because beginning with the full maintenance frequency increases the risk of rash. If a rash develops during the lead-in period, the dose should not be increased until it has resolved and a clinician has assessed the situation. Treatment should be discontinued and urgently assessed if the rash is severe or occurs with systemic symptoms.

• Take each dose at the times directed by the prescriber and follow the supplied medicine instructions.
• Do not change the lead-in period, maintenance schedule, or combination regimen independently.
• If a dose is missed, follow the instructions supplied with the prescription rather than doubling a later dose.
• Ask a pharmacist or prescriber before crushing, splitting, or otherwise altering the tablets.

Consistent use is important in antiretroviral treatment, but consistency does not mean continuing through a potentially serious reaction. Symptoms suggesting a severe skin or liver reaction require prompt medical assessment.

Major safety considerations and interactions

Severe skin reactions and liver toxicity are the most important risks associated with nevirapine. Both can be life-threatening, and the risk is greatest during the early months of treatment. Close clinical assessment and liver-function monitoring are particularly important during the first 18 weeks. Treatment initiation at higher CD4 counts is restricted because it is associated with a greater risk of symptomatic liver toxicity, especially in women.

• Seek prompt medical advice for a rash, particularly if it occurs with fever, blistering, mouth sores, facial swelling, eye irritation, muscle or joint pain, or general illness.
• Watch for possible liver symptoms, including unusual tiredness, nausea, loss of appetite, dark urine, pale stools, pain on the right side of the abdomen, or yellowing of the skin or eyes.
• Tell the prescriber and pharmacist about all prescription medicines, non-prescription products, and supplements because nevirapine affects liver enzymes and has clinically important interactions.
• Nevirapine may reduce the effectiveness of hormonal contraceptives. Discuss an appropriate additional or alternative contraceptive method with a clinician.
• Fatigue or drowsiness may affect driving or the use of machinery. Avoid these activities until you know how the medicine affects you.

Pregnant patients should use nevirapine only as part of specialist HIV care with the required liver and clinical monitoring. Nevirapine passes into human milk, and the supplied product information advises patients receiving it not to breastfeed because of potential effects on the infant and the risk of postnatal HIV transmission.

Other components of an antiretroviral regimen may include nucleoside-based products such as Combivir or Epivir. These links provide product context only. Starting, stopping, or replacing any component of HIV treatment should be managed by the prescriber responsible for the complete regimen.

Canadian access and our ordering policy

Nevirapine is a prescription drug in Canada. Authorized products can be checked in Health Canada's Drug Product Database using details such as the product name, 200 mg strength, tablet dosage form, and Drug Identification Number. The applicable Canadian product monograph and authorized labelling should be identified using the DIN for the specific product supplied.

Our ordering process does not require a prescription document to be uploaded before checkout. Our policy is separate from nevirapine's Canadian prescription status and does not remove the need for an authorized prescriber to select, prescribe, and monitor treatment. Ordering the tablets should not be treated as a way to initiate nevirapine, change an HIV regimen, or restart therapy without clinical guidance.

Suspected adverse reactions can be reported to Health Canada through the Canada Vigilance Program. Urgent symptoms should be assessed promptly rather than waiting to submit a report.

Ordering and delivery details

When ordering from our catalogue, select the Nevirapine 200 mg package quantity that corresponds to the prescription and intended supply period. Review the displayed package price and unit value before proceeding to checkout. An accurate delivery address, including the Canadian postal code where applicable, helps prevent avoidable delivery problems.

1. Select the required 200 mg tablet quantity from the available package options.
2. Review the package price, unit value, and order details before completing checkout.
3. Enter an accurate delivery address and contact information.
4. Keep the order confirmation and contact our support team if clarification is needed.

Our support team is available 24/7 by email, online chat, and phone. Pharmacist support is also available for medicine-related questions. Support can clarify product and ordering information but cannot replace the prescriber responsible for the HIV regimen.

Value-based package choice

The most suitable package is the one that balances the prescribed quantity, anticipated treatment period, expiry date, storage requirements, and ordering practicalities. A 20-tablet package and a 360-tablet package contain the same listed 200 mg oral tablet strength, but they represent very different supply quantities. The largest package should not be chosen automatically because its unit value appears more favourable.

• Confirm the prescribed schedule and expected supply period before selecting a package.
• Account for the lead-in regimen or any possible restart instructions when determining the required count.
• Store the tablets at 20°C to 25°C; excursions from 15°C to 30°C are permitted. Keep the bottle tightly closed and protect it from moisture.
• Check the labelled expiry date and avoid accumulating more medicine than the treatment plan is likely to require.
• Plan reorders early enough to reduce the risk of an unintended interruption.

The package-value comparison can identify differences in cost per tablet, while the prescriber determines whether the quantity and treatment period are medically appropriate. If the available quantities are difficult to compare, our pharmacist-supported team can explain the product options before an order is placed.